Inclusion Criteria:
* Healthy adult male or female aged 18-55 years (age including cut-off values);
* There were no abnormalities in clinically significant vital signs, physical examination, laboratory tests, and 12-lead ECG;
* Weight ≥ 50 kg for males and ≥45 kg for females; Body mass index (BMI) between 18.0 and 26 kg/m2 (including cut-off values, body mass index = weight/height2);
* Females of potential childbearing potential with a negative blood β-HCG test within 72 hours prior to dosing (postmenopausal women who have amenorrhea for at least 12 months are considered non-childbearing and women who are known to have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or ligation, and a pregnancy test is not required);
* Subjects understand and comply with the study process, participate voluntarily, and sign the informed consent form
Exclusion Criteria:
* Subject has a history of malignancy prior to screening, or has been screened for malignancy, and the possibility of malignancy cannot be reasonably ruled out
* Subject has a history of autoimmune disease prior to screening
* γ interferon release assay results ≥ 2 times the upper limit of normal
* Any history of infection requiring hospitalization or receiving antivirals, antibiotics, antifungals, antiparasitic drugs, or vaccinations within 4 weeks prior to the application of the study drug
* Those who have positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody or syphilis antibody
* Patients with a history of previous and/or current heart disease (including New York Heart Association Class III/IV heart failure), gastrointestinal, renal, endocrine, neurological, autoimmune, hematologic (including pancytopenia, aplastic anemia or anaemia, etc.), metabolic (including diabetes), severe lung disease and psychiatric illness
* History of organ transplantation: such as heart, lung, kidney, liver, or hematopoietic stem cell transplantation
